It has become more evident that oncogenic KRAS mutations mediate autocrine effects and crosstalk with the TME, particularly by promoting inflammation and evading the immune response and ultimately leading to tumour progression, invasion and progression7,8. This evidence concerns the gene KRAS and neoplasm.